AGENUS INC — Director's Dealing 2022

Jan 6, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGENUS INC (AGEN)
CIK: 0001098972
Period of Report: 2022-01-04

Reporting Person: O'Day Steven J (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-04	Common Stock	M	100000	—	Acquired	100000	Direct
2022-01-06	Common Stock	S	38679	$3.0597	Disposed	61321	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-04	Restricted Stock Units	$	M	100000	Disposed		Common Stock (100000)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents sales of shares, as a consequence of the vesting of restricted stock units, to cover Federal, state and local tax withholding requirements related to the vesting. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.055 to $3.065. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: On January 4, 2021, the reporting person was granted 100,000 restricted stock units that fully vested on January 4, 2022.